source
- Industry urges FDA to broaden prior-knowledge guidance for gene and cell therapiesIndustry groups have asked the U.S. Food and Drug Administration to broaden its draft guidance on the use of scientifically valid prior knowledge in developing gene therapies that involve genome ed…
- Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma. The ADC, originally discovered by Seagen, will now be adva…